PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr5NE05KM7:TR?= M3i1V|I1NzR6L{eyJIg> NVT2SXM4cW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> MmrkNlYzOjR4OEG=
SH-SY5Y M3vWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[ySXBPOC16IN88US=> NHywW5czPC92OD:3NkBp NGXxbZVqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To NIXsd3gzPjJ{NE[4NS=>
SH-SY5Y  NV3oR4dOSXCxcITvd4l{KEG|c3H5 NEXGd5QyKM7:TR?= M2\ZVFAvPS1{NDDo MWrz[Y5{cXSrenXzJI5mfXKxYnzhd5RwdWFiY3XscJMhfG9iZH;4c5J2[mmlaX6tbY5lfWOnZDDhdI9xfG:|aYO= MXGyOlIzPDZ6MR?=
G 35 SC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:yTIgxNjB3LUKwJO69VQ>? MnzkNlQwPzJiaB?= M1LmcWROW09? NEHYTodqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 M3\DbFI3OTJzMkWx
G 38 SC M3vsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH6[JExNjB3LUKwJO69VQ>? NEnsd2czPC95MjDo NIHSW2JFVVOR NVK3SHpjcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MoDRNlYyOjF{NUG=
G 40 SC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Le4sxNjB3LUKwJO69VQ>? M3K2b|I1Nzd{IHi= NI\IZm1FVVOR M4T0PYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M3PJeVI3OTJzMkWx
G 35 DC NYrOdZdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr2N5VMOC5yNT2yNEDPxE1? NWXrU2RUOjRxN{KgbC=> Mkj2SG1UVw>? NX:4fVF7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MlzhNlYyOjF{NUG=
G 38 DC NFTO[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M160S|AvODVvMkCg{txO MV6yOE84OiCq MYPEUXNQ MmjLbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MUSyOlEzOTJ3MR?=
G 40 DC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS3U4MxNjB3LUKwJO69VQ>? M3u1cFI1Nzd{IHi= NULnZXZ1TE2VTx?= MlPsbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NX3RV5RiOjZzMkGyOVE>
RD M2ftVGFxd3C2b4Ppd{BCe3OjeR?= MonzNU8yNjVxMjFOwG0> NHnCN|Q4OiCq M{\zVYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy Mn7DNlU4PDl|N{i=
TE381.T Ml;rRZBweHSxc3nzJGF{e2G7 MUGxM|EvPS9{IN88US=> NGDWVJc4OiCq MY\pcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> M2C2OVI2PzR7M{e4
RMS13 MnPPRZBweHSxc3nzJGF{e2G7 NGjjT4EyNzFwNT:yJO69VQ>? M3z2fVczKGh? M33vWYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy NEm4fWwzPTd2OUO3PC=>
RH30  MX;BdI9xfG:|aYOgRZN{[Xl? MVOxM|EvPS9{IN88US=> MWe3NkBp NHS1SVNqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? MWOyOVc1QTN5OB?=
VJ NXzUZ3hzSXCxcITvd4l{KEG|c3H5 MV[xM|EvPS9{IN88US=> M33PNFczKGh? MkSxbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> MYCyOVc1QTN5OB?=
HS578T M1z5OGNmdGxiVnnhZoltcXS7IFHzd4F6 M2PCTFAuOyEQvF2= MYO3NkBp NGTwXGtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NV3EO5NQOjV5MkG0NVk>
BT549 M37WcGNmdGxiVnnhZoltcXS7IFHzd4F6 NFm1T5oxNTNizszN M{O0TlczKGh? MlnDbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4TQWVI2PzJzNEG5
MDA-MB-231 MkW0R4VtdCCYaXHibYxqfHliQYPzZZk> NUHDW4Z{OC1|IN88US=> NVTnVW5iPzJiaB?= NF7STGxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NEjB[GEzPTd{MUSxPS=>
MDA-MB-468 M4jlfGNmdGxiVnnhZoltcXS7IFHzd4F6 NFrSZZcxNTNizszN Mm\xO|IhcA>? NWSw[FRUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MlG3NlU4OjF2MUm=
MDA-MB-436 MoLCR4VtdCCYaXHibYxqfHliQYPzZZk> NYDKcoJ2OC1|IN88US=> NUjMUZI2PzJiaB?= NYLhd|hGcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MmHiNlU4OjF2MUm=
SUM149PT NGLaXZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3PwUlAuOyEQvF2= NELQW4E4OiCq M2[4TIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NITD[mYzPTd{MUSxPS=>
MDA-MB-468 NIHyWINHfW6ldHnvckBCe3OjeR?= MYSwMlAyNTFyIN88US=> NXKzV|NpOjRiaB?= NHHafXVld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NHzpUnIzPTd{MUSxPS=>
MDA-MB-231 MUHGeY5kfGmxbjDBd5NigQ>? NYX1d2h3OC5yMT2xNEDPxE1? NUXyPGJUOjRiaB?= M3;aTYRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? Mn3UNlU4OjF2MUm=
HS578T MlvLSpVv[3Srb36gRZN{[Xl? NHXufW4xNjBzLUGwJO69VQ>? NWH5RoRmOjRiaB?= MWjkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh NEjFT2EzPTd{MUSxPS=>
SW872 M3O1UWZ2dmO2aX;uJGF{e2G7 MonSNE4xOS1yLkWg{txO NIi4fJQzPCCq M3nBeZJm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg M{jY[|I1Pjl3NkOy
SW982 MoHQSpVv[3Srb36gRZN{[Xl? NVHlSIc3OC5yMT2wMlUh|ryP NFXPZnczPCCq NVrxT3RDemWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MnO0NlQ3QTV4M{K=
SW872 Mn76RZBweHSxc3nzJGF{e2G7 MXKwMlAyNTBwNTFOwG0> NWKyeFlRPDhiaB?= M3LON4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NEjHTIszPDZ7NU[zNi=>
SW982 MnP4RZBweHSxc3nzJGF{e2G7 NV7GUHc2OC5yMT2wMlUh|ryP M3P5SVQ5KGh? MnjsbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NGLvbJYzPDZ7NU[zNi=>
AGS HG NH22OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYft[IlPUUN3ME2wMlY5KMLzIECuNFMyKM7:TR?= MVyyOFU6PzR5OB?=
AGS LG Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTNXHhKSzVyPUCuNFUhyrFiMD6wNFEh|ryP MkPwNlQ2QTd2N{i=
HGC27 HG NVzmc5B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwM{igxtEhOC5yMkKg{txO MX[yOFU6PzR5OB?=
HGC27 LG NGD2XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DUXWlEPTB;MD6wNkDDuSByLkCwOEDPxE1? NFLzOZYzPDV7N{S3PC=>
MKN45 HG M{PiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHpTWM2OD1zLkCxJOKyKDBwMEWxJO69VQ>? NVT6[3hLOjR3OUe0O|g>
MKN45 LG NFuxU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrlTWM2OD1yLki3JOKyKDBwMEOwJO69VQ>? M2fpU|I1PTl5NEe4
NUGC4 HG M1;lXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnyTWM2OD1zND6wJOKyKDNwOUGzJO69VQ>? MlvyNlQ2QTd2N{i=
NUGC4 LG MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXEVI9iUUN3ME2xOE4xKMLzIEWuN|IyKM7:TR?= MXKyOFU6PzR5OB?=
A549 NUDLTFFETnWwY4Tpc44hSXO|YYm= MoKyNE4zPS9yLkWvNUDPxE1? NYLm[ndMOjRiaB?= NEOwO41qdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 MmDmNlQ{PTF2MkW=
H460 MUjGeY5kfGmxbjDBd5NigQ>? MVSwMlI2NzBwNT:xJO69VQ>? NUnCdYlHOjRiaB?= MXTpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNtcWeqdHz5 NInnPXAzPDN3MUSyOS=>
H661 M3PlOWZ2dmO2aX;uJGF{e2G7 NGTvTZUxNjJ3L{CuOU8yKM7:TR?= NILqTYwzPCCq MkPXbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 M2PwTlI1OzVzNEK1
SAS NUTrbY9JTnWwY4Tpc44hSXO|YYm= M4nEN|AvOjVxMD61M|Eh|ryP NHzJXm4zPCCq NI[2R|RqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= MV2yOFM2OTR{NR?=
UT5 MVTGeY5kfGmxbjDBd5NigQ>? MWSwMlI2NzBwNT:xJO69VQ>? MmrzNlQhcA>? M1;MO4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= NEnE[XQzPDN3MUSyOS=>
FaDu MoD3SpVv[3Srb36gRZN{[Xl? MV2wMlI2NzBwNT:xJO69VQ>? MlLRNlQhcA>? NV3XdIFrcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NEDJe48zPDN3MUSyOS=>
RD MmPNRZBweHSxc3nzJGF{e2G7 NX7kflFFOS9zLkWvNkDPxE1? NI\kZ5k4OiCq NI[wXJhFVVOR MVnpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 M4HpPFI{Pjh2OUK1
TE671 NF34Z4dCeG:ydH;zbZMhSXO|YYm= M4\qN|EwOS53L{Kg{txO MmPnO|IhcA>? NU\3XVZMTE2VTx?= NFyzco9qdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NITpTGczOzZ6NEmyOS=>
RH30  NHS5TYVCeG:ydH;zbZMhSXO|YYm= NVe0R4R7OS9zLkWvNkDPxE1? Mn;SO|IhcA>? NEP5WFlFVVOR MmTTbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> M{W1cVI{Pjh2OUK1
RMS13 MWDBdI9xfG:|aYOgRZN{[Xl? NELWTW0yNzFwNT:yJO69VQ>? NI\idGk4OiCq M2PNdmROW09? NE\IZ3hqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 M4\VPFI{Pjh2OUK1
SUM149PT M4TVTmNmdGxiVnnhZoltcXS7IFHzd4F6 NV\SS4tFOC5|IN88US=> NX;YVYFsPzJiaB?= MlX2[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ NWDyNWhqOjN4MEGwO|Q>
MDA-MB-468 NFTqXmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYLue3F3OC5|IN88US=> M4jjUVczKGh? Ml3B[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ NGXsZXkzOzZyMUC3OC=>
MDA-MB-231 NUDRUW9lS2WubDDWbYFjcWyrdImgRZN{[Xl? M4j3[VAvOyEQvF2= NVL6Zo9DPzJiaB?= NXzOTVhw\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| MmDvNlM3ODFyN{S=
SY5Y M3n2e2Z2dmO2aX;uJGF{e2G7 Mn3tNU42NzJwNT:1JO69VQ>? NYGzb25kOjRiaB?= M2TG[Ylv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= M3v6bVI{Ozd6M{Sx
SKNBE(2c) MUnGeY5kfGmxbjDBd5NigQ>? MojENU42NzJwNT:1JO69VQ>? MnHQNlQhcA>? NHzublJqdmS3Y3XzJGcyyqClZXzsMYN6[2ynIHHydoV{fCCjbnSgZZBweHSxc3nz MorFNlM{Pzh|NEG=
RD NUDhTm1jSXCxcITvd4l{KEG|c3H5 MnnQN{DDvU1? MWKxNkBp NUP4WoxnTE2VTx?= NV\lTZh3e2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> NUn0cIRLOjN|MEC4NFk>
TP5014 NYm4fZA{SXCxcITvd4l{KEG|c3H5 M2fEPVMhyrWP MoDQNVIhcA>? NGPSOWdFVVOR NUDzT4s4e2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> Mn;5NlM{ODB6MEm=
HT1080 NGDOfFdCeG:ydH;zbZMhSXO|YYm= MVuzJOK2VQ>? M1W0b|EzKGh? NV:wb4lHTE2VTx?= NHTBNod{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> M2HNRlI{OzByOEC5
A549 NV6zVpE3TnWwY4Tpc44hSXO|YYm= NEXicJAxNTNwMzFOwG0> NILHWHE4OiCq NH\kfmlqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? MnTYNlMzPTl3OUG=
HCC827 MUHGeY5kfGmxbjDBd5NigQ>? NYHjWGFDOC1|LkOg{txO NFjKZZM4OiCq M1rzT4lv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? NXTVc5o1OjN{NUm1PVE>
H3122 NUjFSYV1TnWwY4Tpc44hSXO|YYm= NInXSpcxNTNwMzFOwG0> MVu3NkBp MnPSbY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV M2OyVVI{OjV7NUmx
TALL-1 NF3MeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSx5qCK|ryP MUe3JIQ> M2Kx[YRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NHG3dYczOzB|OEK3Ny=>
HPB-ALL MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Md48y6oDLzszN MYG3JIQ> MXjk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MVyyN|A{QDJ5Mx?=
DND41 M2nkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyx5qCK|ryP NHfMZZk4KGR? MWTk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MoHlNlMxOzh{N{O=
SUP-T1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjP[5AzOeLCid88US=> MYC3JIQ> NYCxT|lk\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M3vtcFI{ODN6Mkez
PEER NGXEN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[x5qCK|ryP NXXxbJV7PyCm Moqz[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NX7uOotGOjNyM{iyO|M>
ALL-SIL NFzGbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGyTnoxOeLCid88US=> MWi3JIQ> MYnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MWWyN|A{QDJ5Mx?=
KE37 NXzUVpZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TnXFHjiIoQvF2= M1\qdVch\A>? NYXve|Bk\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M1jBR|I{ODN6Mkez
Karpas-45 NWf0UGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrIdlNmOeLCid88US=> NIjVd444KGR? MX3k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MkLLNlMxOzh{N{O=
RPMI-8402 NX74e3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqx5qCK|ryP NE[1fnU4KGR? NYrGdZdM\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MXyyN|A{QDJ5Mx?=
Jurkat M{TtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKx5qCK|ryP Mn\2O{Bl NVO0OZdi\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MYmyN|A{QDJ5Mx?=
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;uVWIy6oDLzszN NF:2eYs4KGR? MkHE[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 Ml2wNlMxOzh{N{O=
PF-382 NHrTOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH4NgKBkc7:TR?= NVXOPXVkPyCm NWOwT5FF\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NXXLRXJSOjNyM{iyO|M>
CCRF-CEM NWDIZY5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrib2U3OeLCid88US=> MVy3JIQ> MnjE[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MlPaNlMxOzh{N{O=
LOUCY NWnTSYRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zVNFHjiIoQvF2= M3nSb|ch\A>? NED6b5dl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MWmyN|A{QDJ5Mx?=
MOLT-16 NXzGSnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\LNgKBkc7:TR?= MWe3JIQ> NHSyTXBl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MU[yN|A{QDJ5Mx?=
MM1S NWG1VlJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMVIh|ryP NX;Xb2RxOjRiaB?= M4r5OGlEPTB;MD61JO69VQ>? NEf5VpIzOjh{OUKzOC=>
NCI-H929 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37SRVAuOiEQvF2= NXr0fZdVOjRiaB?= MXPJR|UxRTBwMkWg{txO NWLPcpQ6OjJ6MkmyN|Q>
KMS12-BM  MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3BNE0zKM7:TR?= M2LoNVI1KGh? MX\JR|Ux97zgMjFOwG0> MoXhNlI5Ojl{M{S=
MDA-MB-436 M2\XO2Z2dmO2aX;uJGF{e2G7 NYLweJRDOSEQvF2= NIfp[YEzPCCq M3H2VJJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= M1TtVFIzPDh6NUmw
SUM149PT NUL6PGF3TnWwY4Tpc44hSXO|YYm= MWGxJO69VQ>? Ml3UNlQhcA>? NHH0fXZz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NHPzSlIzOjR6OEW5NC=>
SUM1315MO2 MlzQSpVv[3Srb36gRZN{[Xl? M2LTUlEh|ryP NUDKWY9POjRiaB?= NXrqc25wemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NIr4dpYzOjR6OEW5NC=>
HCC1937 NWH2cHlzTnWwY4Tpc44hSXO|YYm= MX[xJO69VQ>? NYDrR5ZxOjRiaB?= NYPGNpdRemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MnHHNlI1QDh3OUC=
HCC827 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiwMVMh|ryP NYS2eW8{PzJiaB?= NHrDZmFKSzVyPUCuN{DPxE1? MVWyNVIzODR5NB?=
PC-9  NWj0WpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\LWFExNTNizszN NIHVOGM4OiCq NXu4SYN1UUN3ME2wMlgh|ryP NVz1TFg6OjF{MkC0O|Q>
LN229 NUDqOJp5TnWwY4Tpc44hSXO|YYm= NWmzeZBZOSEQvF2= MlrPOFghcA>? NF\hVmZqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w MnHuNlExPjJ7OUO=
U87 M2f0UWZ2dmO2aX;uJGF{e2G7 MXuxJO69VQ>? Mnz6OFghcA>? MmDubY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? M2rvPVIyODZ{OUmz
U373 NF7tdGtHfW6ldHnvckBCe3OjeR?= MUexJO69VQ>? NW\aSJZKPDhiaB?= NYPib4N4cW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= M1\NPFIyODZ{OUmz
SF767 M3HWR2Z2dmO2aX;uJGF{e2G7 NIP6bWEyKM7:TR?= M{\PO|Q5KGh? NWjEXo1kcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NWrCbIZSOjFyNkK5PVM>
Mel-Juso NVjEOZp1S2WubDDWbYFjcWyrdImgRZN{[Xl? MWmwMlAy6oDVMUFihKnPxE1? MlzhO|IhcA>? MX3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NFLiT3IzOTB2OEe4OS=>
518A2  NVjEV3hRS2WubDDWbYFjcWyrdImgRZN{[Xl? NYHxRnE{OC5yMfMAl|Ex6oDLzszN M2D0ZlczKGh? MmPRbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NVexWYxOOjFyNEi3PFU>
Mel-Juso  MkD4SpVv[3Srb36gRZN{[Xl? NFq1UYExNjByMfMAl|HjiIoQvF2= MmXxNlQhcA>? Mn;Td5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= NH;zZpMzOTB2OEe4OS=>
518A2 M{LyOWZ2dmO2aX;uJGF{e2G7 MYiwMlAxOeLCk{JihKnPxE1? MV:yOEBp MkXLd5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= MX:yNVA1QDd6NR?=
PC3  NX74UlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKyOIg> Mn;SS2k2OMLiPTCxNFAhdk1? M{PGUVIxPTVzME[x
U87MG NWXWNFhkTnWwY4Tpc44hSXO|YYm= M3y2UlAvOS1zIN88US=> MXWyOQKBkWkEoB?= NUjlWZNwTE2VTx?= MYrpcohq[mm2czDQTVNMNW2nZHnheIVlKHOrZ37hcIlv\w>? MnnUNVk3OzN4OEO=
U138MG M2fUcmZ2dmO2aX;uJGF{e2G7 MVywMlEuOSEQvF2= NYjDdXVYOjUkgJnoxsA> MorPSG1UVw>? NUTxelI5cW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= NXvwOpE6OTl4M{O2PFM>
U118MG NWTM[nFWTnWwY4Tpc44hSXO|YYm= MUCwMlEuOSEQvF2= M{[yOFI16oDLaNMg Mm\tSG1UVw>? NUTISJlwcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= MVKxPVY{OzZ6Mx?=
U87MG M{TXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj2TWM2OD1yLkG0JO69VQ>? NGf1VmIyQTV6NEKyOy=>
IGROV-1 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwME[g{txO MV2xPVU5PDJ{Nx?=
DETROIT562 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXIXndKSzVyPUCuNVMh|ryP M4H4[VE6PTh2MkK3
PC3  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq0dXZ2UUN3ME2wMlExKM7:TR?= M3rFblE6PTh2MkK3
SKOV-3 NEjmd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMUKg{txO MkLhNVk2QDR{Mke=
HUVEC M{\xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEig{txO NUTDdJBKOTl3OESyNlc>
UCH-1  Mm\mSpVv[3Srb36gRZN{[Xl? M4nUVFAuPSEQvF2= M1[ycIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBCU1RiYX7kJI1VV1JiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWqxPVUzQDR2MR?=
UCH-1  M1HufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETVPGExNjBzLUGwJO69VQ>? MnzmOkBl NEPEbZpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHTvd4Uh\GWyZX7k[Y51dHl? MmXlNVk2Ojh2NEG=
UCH-1  MmC3RZBweHSxc3nzJGF{e2G7 M4\TTFAvOS1zMDFOwG0> NE\Ifm0zPCCq MWPEUXNQ NH7MbG5qdmS3Y3XzJIFxd3C2b4Ppdy=> MW[xPVUzQDR2MR?=

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ